News

Additionally, the company has earned a $15m milestone payment from Roche related to the initiation of the randomized, double-blind, placebo-controlled, single ascending dose trial. The trial is designed

The patent application allowed by the USPTO (application number 13/063,411) relates to pharmaceutical compositions of growth hormone or parathyroid hormone and the CriticalSorb™ absorption enhancer in a form

All three countries have permission to sell commercial product from their local health authority for the treatment of patients with relapsed or refractory CD30-positive Hodgkin lymphoma (HL) and

ETI-204 is a potential target for future acquisition into the Strategic National Stockpile, the US government’s repository of critical medical supplies for biowarfare preparedness. ETI-204 is the only

This will give key stakeholders and the agency the opportunity to address any outstanding issues before the final policy is presented to the EMA’s management board for endorsement

German pharmaceutical firm Boehringer Ingelheim has received approval from the US Food and Drug Administration (FDA) for Pradaxa (dabigatran etexilate) to treat venous thromboembolism (VTE), which includes both

The FDA acceptance enables Stemline Therapeutics to advance SL-701 into a Phase II trial of adults with glioblastoma multiforme (GBM) in first recurrence. SL-701, a subcutaneously-administered cancer vaccine,

The company has started the launch preparation with its US distributor partner and will commence marketing the product as soon as the launch preparation is completed. According to

Aptiom, a voltage-gated sodium channel blocker, is a new chemical entity approved by the US Food and Drug Administration (FDA) in November 2013, and is available in four